Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2018). A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Invest New Drugs.

Ikeda, Masafumi, Manabu Morimoto, Masaomi Tajimi, Koichi Inoue, Karim A. Benhadji, Michael M. F. Lahn, und Daisuke Sakai. "A Phase 1b Study of Transforming Growth Factor-beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma." Invest New Drugs 2018.

Ikeda, Masafumi, et al. "A Phase 1b Study of Transforming Growth Factor-beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma." Invest New Drugs 2018.